Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug substance plant in Japan. The vaccine maker opted to scrap the project ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...

Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, the steep decline in revenues raises concerns. While sales of its COVID-19 ...

HHS Secretary Robert F. Kennedy Jr. doesn't believe mRNA vaccines for COVID-19 and flu work, so funding is shifting to virus-based vaccines Moderna's stock fell Wednesday after Health and Human ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Wednesday affirmed a district court’s finding of noninfringement in favor of Moderna, Inc. (NASDAQ:MRNA) in its ongoing patent battle with ...

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.’s (NASDAQ:MRNA) mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged ...

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a standard flu shot, the company announced this week. Moderna noted that the new ...

Moderna (NASDAQ:MRNA) is scheduled to announce Q2 earnings results on Friday, August 1st, before market open. The consensus EPS Estimate is -$3.00 and the consensus revenue estimate is $112.56M (-53.3 ...

Moderna MRNA incurred a loss of $2.52 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.92. In the year-ago period, the company had reported a loss of ...